# 510(k) Summary ALPHA Cryptococcal Antigen EIA

This 510(k) summary is submitted in accordance with 21 CFR §807.92

# Owner:

Immuno-Mycologics, Inc.   
2700 Technology Place   
Norman, OK 73071   
Tel: 405-360-4669   
Fax: 405-364-1058   
Contact: Dr. Sean K. Bauman, President & CEO

# Prepared:

February $2 7 ^ { \mathrm { t h } }$ ,2012

# Trade Name:

ALPHA Cryptococcal Antigen EIA

# Common Name:

Cryptococcus Antigen EIA

Classification Name: Antigen, Elisa, Cryptococcus

# Regulation:

866.3165

# Predicate Device:

Meridian's PremierTM Cryptococcal Antigen EIA, K904393

Intended Use:

The ALPHA Cryptococcal Antigen enzyme immunoassay (CrAg EIA) is a qualitative or semi-quantitative (titration) test system for the detection of capsular polysaccharide antigens of Cryptococcus species complex (Cryptococcus neoformans and Cryptococcus gattii) in serum and cerebrospinal fluid (CSF). The ALPHA Cryptococcal Antigen Enzyme Immunoassay is an assay which can be used as an aid in the diagnosis of cryptococcosis. Test results are to be used in conjunction with information available from the patient clinical evaluation and other diagnostic procedures.

# Device Description:

The ALPHA Cryptococcal Antigen Enzyme Immunoassay (EIA) is a direct immunoenzymatic sandwich microplate assay which detects Cryptococcus antigens in serum and CSF. AntiCryptococcus antibodies bound to microwell plates are used as capture antibodies, and horseradish peroxidase (HRP)-conjugated anti-Cryptococcus antibodies are used as detect antibodies. The positive control and standard curve material are composed of cryptococcal capsular polysaccharide antigen in a buffered protein solution with a preservative. In the qualitative procedure, specimens are analyzed undiluted. In the titration procedure, specimens are analyzed after serial dilution in specimen diluent. Either serum or CSF is added to the microwells coated with the capture antibodies and incubated. If the patient specimen contains cryptococcal antigens that are recognized by the capture antibodies, those antigens will become bound to the microwells. The microwells are washed to remove unbound patient material, and HRP-conjugated detect antibody is added to the wells. If Cryptococcus antigens are bound to the microwells by the capture antibodies, the detect antibody will also become bound to the microwells. The wells are then washed to remove any unbound detect antibody. Next, tetramethylbenzidine (TMB) substrate is added to the microwells, and in the presence of HRP, a blue color will develop. The reaction is stopped by the addition of a stop solution. The optical density (OD) is determined with a microplate reader at $4 5 0 \mathrm { n m }$ with reference at $6 3 0 \mathrm { n m }$ (reference is optional).

# Comparison with Predicate:

A comparison of the similarities and differences between the ALPHA Cryptococcal Antigen EIA and the predicate device is presented in the tables below (Table 1).

Table 1. Similarities and Differences between ALPHA Cryptococcal Antigen EIA and Premier Cryptococcal Antigen EIA   

<table><tr><td rowspan=1 colspan=3>SIMLARITIESAssay             ALPHA Cryptococcal Antigen EIA       Premier Cryptococcal Antigen EIAFeature                          New Device                                     K904393Intended Use</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Detection of capsular polysaccharide antigens</td><td rowspan=1 colspan=1>Detection of capsular polysaccharide antigens :</td></tr><tr><td rowspan=1 colspan=1>Indication For Use</td><td rowspan=1 colspan=1>Aid in the diagnosis of cryptococcosis</td><td rowspan=1 colspan=1>Aid in the diagnosis of cryptococcosis</td></tr><tr><td rowspan=1 colspan=3>Device Description</td></tr><tr><td rowspan=1 colspan=1>Assay Principle</td><td rowspan=1 colspan=1>EIA</td><td rowspan=1 colspan=1>EIA</td></tr><tr><td rowspan=1 colspan=1>Sample Matrix</td><td rowspan=1 colspan=1>Serum &amp; CSF</td><td rowspan=1 colspan=1>Serum &amp; CSF</td></tr><tr><td rowspan=1 colspan=1>Assay components</td><td rowspan=1 colspan=1>Antibody coated 96-well microplate, wash buffer,positive control, enzyme conjugate, TMB substrate,stop solution, sample diluent</td><td rowspan=1 colspan=1>Antibody coated 96-well microplate, wash buffer,positive control, enzyme conjugate, TMB substrate,stop solution, sample diluent</td></tr><tr><td rowspan=1 colspan=1>Detection Chemistry</td><td rowspan=1 colspan=1>HRP + TMB</td><td rowspan=1 colspan=1>HRP + TMB</td></tr><tr><td rowspan=1 colspan=1>Specimen pre-treatment?</td><td rowspan=1 colspan=1>none</td><td rowspan=1 colspan=1>none</td></tr><tr><td rowspan=1 colspan=1>Controls/Standard</td><td rowspan=1 colspan=1>Cryptococcal Antigen</td><td rowspan=1 colspan=1>Cryptococcal Antigen</td></tr><tr><td rowspan=1 colspan=1>Microplate</td><td rowspan=1 colspan=1>96-well microplate coated with antigen</td><td rowspan=1 colspan=1>96-well microplate coated with antigen</td></tr></table>

<table><tr><td>Assay</td><td>DIFFERENCES ALPHA Cryptococcal Antigen EIA</td><td>Premier Cryptococcal Antigen EIA K904393</td></tr><tr><td>Feature Device Description</td><td>New Device</td><td></td></tr><tr><td>Output</td><td>Positive or Negative Only</td><td>Positive, Negative, and Indeterminate</td></tr><tr><td>Reagent Application</td><td>Pipette or equivalent</td><td>Reagent Droppers</td></tr><tr><td>Optional Visual Read</td><td>No</td><td>Yes</td></tr></table>

# Analytical Performance Summary

A. Precision Studies Precision Test Methods:

The ALPHA Cryptococcal Antigen EIA was evaluated for reproducibility and precision by spiking serum and mock CSF with cryptococcal antigen to produce a panel consisting of a negative sample, a high negative $\left( \mathbf { C } _ { 5 } \right)$ sample, a low positive sample and a moderate positive sample. This panel was tested twice per day at three sites [Immuno-Mycologics, Inc., a national reference lab, and a clinical lab] with a total of five operators over a five-day period in order to determine both the inter-lab and the intra-lab reproducibility and precision of the assay. The results of this study are shown in the table below.

Below is the data from the reproducibility study presented by percent positive for each specimen type.   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>IMMY</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>National Reference Lab</td><td rowspan=1 colspan=1>nce Lab</td><td rowspan=1 colspan=2>Clinical Lab</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Comb</td><td rowspan=1 colspan=2>Combined Data (3 Sites)</td></tr><tr><td rowspan=1 colspan=1>Descriptlon</td><td rowspan=1 colspan=1>Type</td><td rowspan=1 colspan=1>AveO.D.</td><td rowspan=1 colspan=1>StdDev</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>AveO.D.</td><td rowspan=1 colspan=1>StdDev</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>AveO.D.</td><td rowspan=1 colspan=1>StdDev</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>AveO.D.</td><td rowspan=1 colspan=1>Std.Dev.</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Blank</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>0.066</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>17.8</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0027</td><td rowspan=1 colspan=1>3686.2</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>0.046</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>74.67</td></tr><tr><td rowspan=1 colspan=1>CRYPC1</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>1.814</td><td rowspan=1 colspan=1>0.078</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>1.973</td><td rowspan=1 colspan=1>0.1083</td><td rowspan=1 colspan=1>S.5</td><td rowspan=1 colspan=1>2.473</td><td rowspan=1 colspan=1>0.158</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>2.059</td><td rowspan=1 colspan=1>0.295</td><td rowspan=1 colspan=1>14.34</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0.022</td><td rowspan=1 colspan=1>0.011</td><td rowspan=1 colspan=1>48.7</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>0.0058</td><td rowspan=1 colspan=1>48.8</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>25.4</td><td rowspan=1 colspan=1>0.018</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>50.25</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>19.2</td><td rowspan=1 colspan=1>0.028</td><td rowspan=1 colspan=1>0.0077</td><td rowspan=1 colspan=1>27.7</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>26.51</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0.420</td><td rowspan=1 colspan=1>0.041</td><td rowspan=1 colspan=1>9.7</td><td rowspan=1 colspan=1>0.338</td><td rowspan=1 colspan=1>0.0436</td><td rowspan=1 colspan=1>12.9</td><td rowspan=1 colspan=1>0.372</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>0.377</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>14.16</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>1.683</td><td rowspan=1 colspan=1>0.229</td><td rowspan=1 colspan=1>13.6</td><td rowspan=1 colspan=1>1.666</td><td rowspan=1 colspan=1>0.1281</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>1.959</td><td rowspan=1 colspan=1>0.205</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>1.756</td><td rowspan=1 colspan=1>0.229</td><td rowspan=1 colspan=1>13.05</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>0.065</td><td rowspan=1 colspan=1>0.018</td><td rowspan=1 colspan=1>27.8</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>0.0087</td><td rowspan=1 colspan=1>15.1</td><td rowspan=1 colspan=1>0.099</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>0.072</td><td rowspan=1 colspan=1>0.022</td><td rowspan=1 colspan=1>29.85</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>0.179</td><td rowspan=1 colspan=1>0.020</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>0.174</td><td rowspan=1 colspan=1>0.0190</td><td rowspan=1 colspan=1>10.9</td><td rowspan=1 colspan=1>0.298</td><td rowspan=1 colspan=1>0.027</td><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>0.211</td><td rowspan=1 colspan=1>0.059</td><td rowspan=1 colspan=1>28.09</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>0.346</td><td rowspan=1 colspan=1>0.028</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>0.339</td><td rowspan=1 colspan=1>0.0319</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>0.533</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.397</td><td rowspan=1 colspan=1>0.092</td><td rowspan=1 colspan=1>23.27</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive</td><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>0.629</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>0.606</td><td rowspan=1 colspan=1>0.0443</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.929</td><td rowspan=1 colspan=1>0.056</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>0.707</td><td rowspan=1 colspan=1>0.149</td><td rowspan=1 colspan=1>21.13</td></tr></table>

<table><tr><td>Serum</td><td></td><td>Site 1 % Positive</td><td>Site 2 % Positive</td><td>Site 3 % Positive</td><td>Overall % Positive</td></tr><tr><td></td><td>Negative</td><td>0%</td><td>0%</td><td>0%</td><td>0% 1</td></tr><tr><td></td><td>High Negative Low Positive</td><td>0% 100%</td><td>0% 100%</td><td>0% 100%</td><td>0% 100%</td></tr><tr><td></td><td>Moderate Positive</td><td>100%</td><td>100%</td><td>100%</td><td>100%</td></tr><tr><td>CSF</td><td></td><td>Site 1 %</td><td>Site 2 % Positive</td><td>Site 3 %</td><td>Overall %</td></tr><tr><td></td><td>Negative</td><td>Positive 0%</td><td>0%</td><td>Positive 0%</td><td>Positive 0%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Low Positive</td><td>100%</td><td>100%</td><td></td><td></td></tr><tr><td></td><td>High Negative</td><td>0%</td><td>0%</td><td>83%</td><td>24%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>100%</td><td>100%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Moderate Positive</td><td>100%</td><td>100%</td><td>100%</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>100%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>

# B.Analytical Sensitivity (Lower limits of the assay)

# LoB and LoD Testing Methods

Analytical sensitivity was estimated at IMMY according to Clinical and Laboratory Standards Institute (CLSI) EP-17A. The limit of the blank (LoB) was estimated by running 80 replicates of normal human serum and 80 replicates of artificial CSF. The initial limit of detection (LoD) was estimated by running 20 replicates of 4 concentrations near the LoB in both serum and CSF.

The LoD was established by testing 24 replicates of both serum and CSF spiked with Cryptococcal antigen at a range of concentrations near the initial LoD. Results were considered positive if they yielded a blanked OD that was greater than the cut-off.

Analysis shows that for serum the LoD was $5 . 3 ~ \mathrm { { n g / m l } }$ For CSF, the LoD was $1 . 7 \mathrm { n g / m l }$ .

C. Analytical Specificity (Cross-Reactivity)

Analytical specificity for the ALPHA Cryptococcal Antigen EIA was determined by running potentially cross-reacting medical conditions unrelated to cryptococcosis. The following specimens were run on one lot of the ALPHA Cryptococcal Antigen EIA. A total of 118 serum specimen and 15 fungal culture filtrates were tested. Culture filtrates were tested at three different dilutions: undiluted, 1:10, and 1:100. Dilutes were made in 1X Specimen Diluent. Percent positive was determined for each condition.

As expected, some fungal cross-reactivity was observed. One Aspergillus galactomannan positive specimen (positive by Bio-Rad's PlateliaTM Aspergillus EIA) was positive in the ALPHA Cryptococcal Antigen EIA and Paracoccidioides brasiliensis culture filtrates undiluted and 1:10 were positive as well. The total percent positive for fungal pathologies was $3 . 9 \%$ , well below the acceptance criteria of $10 \%$ However, Paracoccidioides brasiliensis Culture Filtrate had a total percent positive of $67 \%$ .

Rheumatoid factor is known to cause false-positive results in the Cryptococcal latex agglutination method. Rheumatoid factor did not cause false positives in the ALPHA Cryptococcal Antigen EIA between the range of $1 1 2 \ \mathrm { I U / m l }$ and $6 4 7 9 \ [ \mathrm { U / m l }$ . The normal reference range for rheumatoid factor is $0 { \cdot } 1 4 ~ [ \mathrm { I U / m l } ]$ .

D. Interference Studies

In addition to the cross-reactivity study, interference testing was also performed on five icteric, five hemolyzed, and five lipemic serum specimens. Each specimen was spiked with cryptococcal antigen at three times the C95 concentration. All specimens were then tested at IMMY, on one lot of the ALPHA Cryptococcal Antigen EIA in triplicate: spiked and unspiked.

All of the unspiked specimens had negative results on the ALPHA Cryptococcal Antigen EIA. All spiked specimens were positive, thus, these types of serum specimens do not interfere with the ALPHA Cryptococcal Antigen EIA.

E. High Dose Hook Effect

The effects of high doses were determined by spiking a serum specimen pool that was negative by the IMMY Latex-Cryptococcus Antigen Detection System and ALPHA Cryptococcal Antigen EIA, with cryptococcal antigen at $1 \mathrm { m g / m l }$ and testing it in triplicate at IMMY on one lot of ALPHA Cryptococcal Antigen EIA, according to the package insert.

It was observed that at extremely high concentrations, the signal can be reduced due to the high dose hook effect. Although the signal is reduced leading to lower than expected EIA values, the result is still positive. The semi-quantitative titration procedure can differentiate between a low EIA score due to the high dose hook effect and a low ElA score due to low concentrations of Cryptococcal Antigen.

# F. Specimen Acceptance Criteria - Freeze-Thaw Study

Three CrAg-Negative human CSF specimens and four CrAg-Negative human serum specimens were spiked with concentrations of Cryptococcal Antigen near and slightly above the cutoff of the assay. The specimens were tested on the ALPHA $\operatorname { C r } \mathbf { A } \mathbf { g }$ EIA immediately after spiking and then they were frozen at $< - 2 0 C$ for the Day 0 time point. The specimens were then divided into three aliquots and tested as follows:

Aliquot 1  Tested daily in triplicate, subjected to a freeze-thaw cycle each day Aliquot 2  Frozen for 1 week, thawed and tested in triplicate Aliquot 3 - Frozen for 2 weeks, thawed and tested in triplicate

![](images/0de1095f1a7dfd8a7e316e6798444a62e23cbbf26fce2dd9ddfe160e2ce82be7.jpg)

Specimens may be stored for up to one week at $\leq - 2 0 { } ^ { \circ } C$ Reductions in OD values after one week of specimen storage at $\leq - 2 0 ^ { \circ } \mathrm { C }$ and after multiple freeze thaws may occur. Since a reduction in OD values was observed, it is possible that a fresh, very low-positive specimen ner 0.0 Blanked ) could bee egative   is sore or ne week.If osble, multiple freeze-thaw cycles should be avoided to minimize any effects due to specimen storage.

G. Linearity

N/A

H. Assay cut-off

The assay cutoff was determined through ROC analysis using the IMMY CrAg Lateral Flow Assay (LFA) as the means of classifying a specimen as a true positive or negative. The

intent of this classification system was to match the sensitivity and specificity of this assay to the sensitivity and specificity of the LFA.

ROC Analysis was performed on a dataset consisting of 995 combined serum and CSF specimens.

ROC Analysis suggested a blanked OD cutoff value of greater than 0.265 which yielded a sensitivity of $9 7 . 4 \%$ and a specificity of $9 9 . 9 \%$ when compared to the IMMY CrAg LFA as the reference method.

This cutoff was confirmed through the method comparison comparing the results from the IMMY Cryptococcal Antigen EIA to the predicate device.

Cut-Off Conclusions:

In summary our cut-offs are defined based on the blanked OD from the ROC analysis:

<table><tr><td colspan="2"></td></tr><tr><td>x≤0.265</td><td>Negative</td></tr><tr><td>x &gt;0.265</td><td>Positive</td></tr></table>

# F. Method Comparison

# Comparison to Another Manufacturer's Device

A three-site (IMMY and two national reference laboratories) split-specimen comparison study was performed on both serum and CSF specimens that had been submitted for cryptococcal antigen ElA testing. A total of 1782 specimens (CSF $\mathtt { n } { = } 4 2 6$ ; serum $n { = } 1 3 5 6$ were tested in both the ALPHA Cryptococcal Antigen EIA and a commercial Cryptococcal antigen EIA according to their respective package inserts.

The resulting data from the split sample comparison is shown in the tables below.

Serum 2x2 Contingency Table   

<table><tr><td rowspan=3 colspan=1>IMMY EIA (+)IMMY EIA (-)</td><td rowspan=1 colspan=1>Commercial EIA (+)</td><td rowspan=1 colspan=1>Commercial EIA (-)</td></tr><tr><td rowspan=1 colspan=1>131</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1195</td></tr></table>

CSF 2x2 Contingency Table

<table><tr><td></td><td>Commercial EIA (+) Commercial EIA (-)</td><td></td></tr><tr><td>IMMY EIA (+)</td><td>29</td><td>3</td></tr><tr><td>IMMY EIA (-)</td><td>2</td><td>392</td></tr></table>

The combined results, excluding indeterminates, were analyzed for percent agreement positive, percent agreement negative and overall percent agreement according to Clinical and Laboratory Standards Institute (CLSI) EP12-A2. The results of this analysis are shown in the table below.

<table><tr><td></td><td>Dataset</td><td>Point Estimate</td><td>95% Confidence Interval</td></tr><tr><td>% Agreement Positive</td><td>Serum Only</td><td>98.5%</td><td>94.7% - 99.6%</td></tr><tr><td rowspan="3">% Agreement Negative % Agreement Positive</td><td>Serum Only</td><td>97.7%</td><td>96.7% - 98.4%</td></tr><tr><td></td><td></td><td></td></tr><tr><td>CSF Only</td><td>93.5%</td><td>79.3% - 98.2%</td></tr><tr><td>% Agreement Negative</td><td>CSF Only</td><td>99.2%</td><td>97.8% - 99.7%</td></tr></table>

# Comparison to IMMY CrAg Lateral Flow Assay

A three-site (IMMY and two national reference laboratories) split-specimen comparison study was performed on both serum and CSF specimens that had been submitted for cryptococcal antigen EIA testing. A total of 1782 specimens (CSF $\scriptstyle \mathtt { n } = 4 2 6$ ; serum $\scriptstyle \mathbf { n } = 1 3 5 6$ were tested in both the ALPHA Cryptococcal Antigen EIA and the IMMY Cryptococcal Antigen Lateral Flow Assay (LFA) according to their respective package inserts.

The ALPHA Cryptococcal Antigen EIA performs similarly to the IMMY Cryptococcal Antigen Lateral Flow Assay (LFA) with $9 6 . 9 \%$ and $9 3 . 8 \%$ Agreement Positive, and $9 9 . 8 \%$ and $9 9 . 5 \%$ Agreement Negative to the LFA in serum and CSF, respectively.

# Conclusion

The information submitted in this premarket notification is complete and supports a substantial equivalence decision.

Immuno-Mycologics, Inc. c/o Sean K. Bauman, Ph.D. 2700 Technology Place Norman, OK 73071

Re: k120946 Trade/Device Name: ALPHA Cryptococcal Antigen ElA Regulation Number: 21 CFR $\ S 8 6 6 . 3 1 6 5$ EY Regulation Name: Cryptococcus neoformans serological reagents Regulatory Class: Class II Product Code: MDU Dated: October 25, 2012 Received: October 26, 2012

Dear Dr. Bauman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

Page 2 - Sean K. Bauman

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostics and Radiological Health at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours, Uwe Scherf for

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostics   
And Radiological Health   
Center for Devices and Radiological Health

# Indications for Use Statement

510(k) Number (if known): K120946

Device Name: ALPHA Cryptococcal Antigen Enzyme Immunoassay

Indications for Use: The ALPHA Cryptococcal Antigen enzyme immunoassay (CrAg EIA) is a qualitative or semiquantitativettration)est systemorthedetection capsular polysaccharide antns of Cryptococcus species complex (Cryptococcus neoformans and Cryptococcus gatti) in serum and cerebrospinal fluid (CSF).The ALPHA Cryptococcal Antigen Enzyme Immunoassay is an assay which can be used as an aid in the diagnosis of cryptococcosis. Test results are to be used in conjunction with information available from the patient clinical evaluation and other diagnostic procedures.

Concyencef CDRH, Ofice In Vit Diagnostic Devices (OVD) Un S0

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k). 6 120946